Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the ...

Meanwhile, AstraZeneca's Imfinzi (durvalumab) plus chemo is being tested as an adjuvant therapy for stage II-III NSCLC, regardless of PD-L1 status, in the MERMAID-1 trial. Image Phil Taylor ...

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

G12D-selective inhibitor zoldonrasib encouraged both the company and the analysts. Initial study data produced a 61% ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

Surgery remains the mainstay of treatment for early-stage [non-small cell lung cancer (NSCLC)], regardless of age,” researchers wrote in the Journal of ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Taletrectinib can be effective in patients with TKI-naïve or TKI-pretreated advanced NSCLC, a pooled analysis suggests.